These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 20158090

  • 21. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
    Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, PROactive Investigators.
    Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
    [Abstract] [Full Text] [Related]

  • 22. PROactive: time for a critical appraisal.
    Betteridge DJ, DeFronzo RA, Chilton RJ.
    Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].
    Kawamori R.
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():671-7. PubMed ID: 21766679
    [No Abstract] [Full Text] [Related]

  • 28. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Holleman F, Gerdes VE, de Vries JH, Hoekstra JB.
    Ned Tijdschr Geneeskd; 2006 Feb 18; 150(7):358-60. PubMed ID: 16523797
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Kaku K, Daida H, Kashiwagi A, Yamashina A, Yamazaki T, Momomura S, Iwase T, Yamasaki Y, Nagatsuka K, Kitagawa K, Kawamori R.
    Curr Med Res Opin; 2009 Dec 18; 25(12):2925-32. PubMed ID: 19835463
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
    Yoshii H, Onuma T, Yamazaki T, Watada H, Matsuhisa M, Matsumoto M, Kitagawa K, Kitakaze M, Yamasaki Y, Kawamori R, PROFIT-J Study Group.
    J Atheroscler Thromb; 2014 Dec 18; 21(6):563-73. PubMed ID: 24477028
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW.
    Diabetes Obes Metab; 2014 Dec 18; 16(12):1257-64. PubMed ID: 25155146
    [Abstract] [Full Text] [Related]

  • 35. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A, Forst T.
    Expert Opin Pharmacother; 2006 Mar 18; 7(4):463-76. PubMed ID: 16503818
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Mar 18; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 39. Pioglitazone for type 2 diabetes mellitus.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.
    Cochrane Database Syst Rev; 2006 Oct 18; 2006(4):CD006060. PubMed ID: 17054272
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 18; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.